Literature DB >> 31212162

Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome.

Payal P Khincha1, Ana F Best2, Joseph F Fraumeni3, Jennifer T Loud4, Sharon A Savage4, Maria Isabel Achatz5.   

Abstract

Li-Fraumeni syndrome (LFS) is a rare autosomal dominant cancer predisposition syndrome with exceptionally high lifetime cancer risks, caused primarily by germline TP53 variants. Early-onset breast cancer is the most common cancer in women with LFS. Associations between female reproductive factors and breast cancer risk have been widely studied in the general population and BRCA1/2 mutation carriers but not in LFS. We evaluated whether reproductive factors are associated with breast cancer in LFS. Questionnaire data were collected for 152 women with confirmed germline TP53 variants enrolled in the National Cancer Institute's LFS study (NCT01443468); of which, 85 had breast cancer, confirmed by pathology/medical reports. Fisher's exact test and Cox proportional hazards were used to calculate the effect of reproductive factors on breast cancer risk. Lifetime breastfeeding for at least 7 months was associated with lower breast cancer risk (hazard ratio [HR] 0.57, p = 0.05). Parity did not independently change breast cancer risk (HR 1.08, p = 0.8) but suggested an increased risk with older age at first live birth (HR 2.14, p = 0.05). Age at menarche (HR 1.09, p = 0.24) and use of oral contraceptives (HR 0.88; p = 0.7) did not significantly affect breast cancer risk. In this first study of reproductive factors and breast cancer in women with LFS, breastfeeding was observed to be protective against breast cancer risk, especially with at least 7 months of lifetime breastfeeding. Older age at first live birth was suggested to slightly increase breast cancer risk. Larger prospective studies of reproductive factors are warranted in women with LFS before making definitive clinical recommendations. Published by Elsevier Ltd.

Entities:  

Keywords:  Breast cancer; Breastfeeding; Li-Fraumeni syndrome; Reproductive; TP53

Mesh:

Substances:

Year:  2019        PMID: 31212162      PMCID: PMC8785220          DOI: 10.1016/j.ejca.2019.05.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  31 in total

1.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.

Authors: 
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

Review 2.  Epidemiology of breast cancer.

Authors:  T J Key; P K Verkasalo; E Banks
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

Review 3.  Inherited TP53 Mutations and the Li-Fraumeni Syndrome.

Authors:  Tanya Guha; David Malkin
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

4.  Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.

Authors:  Serena Masciari; Deborah A Dillon; Michelle Rath; Mark Robson; Jeffrey N Weitzel; Judith Balmana; Stephen B Gruber; James M Ford; David Euhus; Alexandra Lebensohn; Melinda Telli; Stephen M Pochebit; Georgios Lypas; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2012-03-04       Impact factor: 4.872

5.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

Review 6.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

7.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

8.  Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jacek Gronwald; Henry T Lynch; Andrea Eisen; Susan L Neuhausen; Nadine Tung; Peter Ainsworth; Jeffrey N Weitzel; Tuya Pal; William D Foulkes; Charis Eng; Christian F Singer; Leigha Senter; Ping Sun; Jan Lubinski; Steven A Narod
Journal:  Breast Cancer Res Treat       Date:  2018-05-17       Impact factor: 4.872

Review 9.  Modifiers of risk of hereditary breast and ovarian cancer.

Authors:  Steven A Narod
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

10.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  2 in total

Review 1.  Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.

Authors:  Sylwia Pietrasik; Gabriela Zajac; Jan Morawiec; Miroslaw Soszynski; Michal Fila; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

2.  Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.

Authors:  Cristina Fortuno; Jessica Mester; Tina Pesaran; Jeffrey N Weitzel; Jill Dolinsky; Amal Yussuf; Kelly McGoldrick; Judy E Garber; Sharon A Savage; Payal P Khincha; D Gareth Evans; Maria Isabel Achatz; Kim E Nichols; Kara N Maxwell; Joshua D Schiffman; Renata Sandoval; Paul A James; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2020-06-12       Impact factor: 4.700

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.